Home > Oncology > ELCC 2019 > Current Management of Early Stage NSCLC > Treatment Options in Early NSCLC

Treatment Options in Early NSCLC

Presented By
Dr Walter Weder, Dr Raffaele Califano
Conference
ELCC 2019
Trial
CALGB 9633

Both adjuvant and neo-adjuvant chemotherapy are standard-of-care for fit patients, at least for those with resected or resectable stage 2 or 3 non-small cell lung cancer (NSCLC). There is a strong rationale for perioperative immune checkpoint blockade and targeted therapies, such as ALK- and EGFR-directed tyrosine kinase inhibitors (TKIs).

Should we use neoadjuvant chemotherapy, and not upfront surgery in combination with adjuvant treatment of early stage NSCLC? The answer is still not clear. A previous trial showed no statistically significant differences in disease-free survival (DFS) with the addition of preoperative or adjuvant chemotherapy to surgery [1]. In contrast, a recently published analysis of the National Cancer Database showed that both adjuvant and neoadjuvant chemotherapy result in better survival rates than surgery alone in patients with stage 2 or 3 lung cancer [2].

“The guidelines of the European Society of Thoracic Surgeons (ESTS...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on